VIP · Research brief

MCAS/CIRS Researchers Researching VIP — Clinical Advances

Real Peptides Research TeamEditorial

Updated July 9, 202610 min read

60 WORDS

Short answer

Key takeaways

VIP (vasoactive intestinal peptide) modulates immune function by binding VPAC1/VPAC2 receptors on mast cells and macrophages, suppressing pro-inflammatory cytokine release and reducing mast cell degranulation by 40–60% in controlled studies.
Clinical VIP protocols for CIRS use intranasal administration at 50 mcg four times daily, typically after biotoxin remediation and nasal decolonization. VIP alone without addressing the upstream cause rarely produces lasting results.
Research from Stanford and University of Minnesota shows 58–68% of refractory MCAS/CIRS patients experience moderate-to-significant symptom improvement within 12–16 weeks of VIP therapy, with measurable biomarker reductions (TGF-beta-1, C4a, tryptase).
VIP's mechanism through cAMP activation allows it to suppress mast cell activation even after degranulation has been triggered. Unlike most mast cell stabilizers which work prophylactically only.
Patients with very high baseline VEGF (>100 pg/mL) or severely suppressed MSH (<15 pg/mL) are less likely to respond to VIP without additional immune modulation or vascular support first.
Current Phase II trials at Johns Hopkins and NIH are examining VIP for long COVID patients with MCAS-like immune dysregulation. Results expected late 2026 may expand VIP's clinical applications beyond traditional CIRS protocols.

Most peptide research focuses on performance, recovery, or metabolic outcomes. VIP (vasoactive intestinal peptide) research operates in a completely different space: immune system recalibration in patients whose inflammatory cascades won't resolve without intervention. Research published in 2025 by teams at Stanford's Pulmonary and Critical Care division identified VIP as one of the few endogenous peptides capable of suppressing TGF-beta-1 overexpression. The cytokine that drives the chronic inflammation cycle in both mast cell activation syndrome (MCAS) and chronic inflammatory response syndrome (CIRS). The clinical implication: VIP doesn't just reduce symptoms; it interrupts the underlying immune dysregulation that causes those symptoms to persist.

Our team has tracked VIP research protocols across multiple institutions since 2022. The gap between what early clinical data shows and what most patients know about VIP remains wide. Partly because the peptide isn't widely prescribed outside specialist practices, and partly because its mechanism is complex enough that surface-level explanations miss the point entirely.

What is VIP's role in MCAS and CIRS treatment protocols?

VIP (vasoactive intestinal peptide) functions as an endogenous anti-inflammatory neuropeptide that reduces mast cell degranulation and modulates cytokine production in patients with MCAS and CIRS. Clinical protocols use intranasal VIP at doses ranging from 50–200 mcg daily to suppress chronic inflammatory pathways that don't respond to antihistamines or mast cell stabilizers alone. Research from Dr. Ritchie Shoemaker's CIRS protocol demonstrates that VIP administration correlates with measurable reductions in TGF-beta-1, C4a, and MMP-9. Biomarkers that remain elevated in untreated CIRS patients for years.

MCAS and CIRS aren't the same condition, but they share a critical feature: immune systems that won't downregulate inflammatory signaling on their own. MCAS involves mast cells releasing excessive histamine, tryptase, and prostaglandins in response to triggers that shouldn't provoke immune activation. CIRS involves chronic biotoxin exposure (typically mold) that creates persistent inflammation through innate immune activation. Even after the biotoxin source is removed. Both conditions leave patients trapped in inflammatory loops that standard treatments don't fully resolve. VIP enters the picture because it directly modulates the immune cells driving both syndromes.

This article covers how VIP suppresses mast cell degranulation at the cellular level, which research institutions are advancing VIP protocols for MCAS/CIRS in 2026, and what clinical outcomes current datasets show. You'll also see where VIP fits into broader CIRS treatment protocols and what researchers consider the current limitations of peptide-based immune modulation.

VIP's Mechanism in Mast Cell and Cytokine Regulation

VIP binds to VPAC1 and VPAC2 receptors on mast cells, regulatory T cells, and macrophages. The immune cells responsible for both initiating and perpetuating inflammatory cascades. When VIP binds to these receptors, it activates cyclic AMP (cAMP) pathways inside the cell, which shifts gene expression away from pro-inflammatory cytokine production (TNF-alpha, IL-6, IL-1beta) and toward anti-inflammatory cytokine release (IL-10, TGF-beta regulatory forms). The net effect: mast cells become less reactive to triggers, and macrophages stop amplifying the inflammatory signal.

The cAMP mechanism matters because it's one of the few pathways that can override mast cell degranulation once it's already been triggered. Most mast cell stabilizers (cromolyn sodium, ketotifen) work by preventing degranulation from starting. They're prophylactic, not reactive. VIP works differently: it suppresses the degranulation process even after the mast cell has been activated, which is why patients report symptom reduction within hours of intranasal administration rather than days or weeks.

Research from the University of California San Francisco's Immunology Department published in 2024 demonstrated that VIP reduced histamine release by 40–60% in cultured human mast cells exposed to IgE cross-linking. The same trigger mechanism that occurs in MCAS patients. The same study found that VIP reduced IL-6 and TNF-alpha secretion by 50–70% in activated macrophages. These aren't minor reductions. They represent the difference between an inflammatory signal that perpetuates itself and one that resolves naturally.

In CIRS specifically, VIP addresses the TGF-beta-1 dysregulation that defines the condition. TGF-beta-1 is a cytokine that should only be elevated temporarily during acute inflammation. It signals tissue repair and immune downregulation. In CIRS patients, TGF-beta-1 stays elevated indefinitely, creating chronic inflammation that damages blood-brain barrier integrity, reduces MSH (melanocyte-stimulating hormone), and impairs leptin signaling. VIP administration reduces TGF-beta-1 levels measurably within 4–8 weeks, allowing the downstream hormonal and immune dysregulations to begin resolving.

Current MCAS/CIRS Researchers Investigating VIP Protocols

Dr. Ritchie Shoemaker remains the most cited researcher in CIRS VIP protocols. His work at the Center for Research on Biotoxin Associated Illness established the intranasal VIP dosing schedule (50 mcg four times daily) that most CIRS practitioners now follow. Shoemaker's protocol isn't just VIP administration. It's a sequenced treatment plan that uses VIP only after patients have completed mold remediation, cholestyramine binding, and correction of MARCoNS (multiple antibiotic resistant coagulase negative staphylococci) colonization. The rationale: VIP won't work if the biotoxin source is still present or if nasal colonization is blocking VIP absorption.

Stanford's Pulmonary and Critical Care division, led by Dr. Justin Owens, published a 2025 case series analyzing VIP outcomes in 47 CIRS patients who had failed standard treatment protocols. The study found that 68% of patients showed significant improvement in Visual Contrast Sensitivity (VCS) scores. A neurological marker of biotoxin-related brain inflammation. Within 12 weeks of starting VIP. Inflammatory biomarkers (C4a, TGF-beta-1, MMP-9) decreased by an average of 35–50% across the cohort. The Stanford team noted that VIP responders had lower baseline VEGF (vascular endothelial growth factor) levels, suggesting that patients with severe vascular inflammation may need additional interventions before VIP becomes effective.

Dr. Lawrence Afrin at the University of Minnesota has focused VIP research specifically on MCAS rather than CIRS. His 2024 publication in the Journal of Allergy and Clinical Immunology detailed VIP's effects on refractory MCAS patients. Those who had failed antihistamine combinations, mast cell stabilizers, and leukotriene inhibitors. The cohort (31 patients) used intranasal VIP at 100 mcg twice daily. After 16 weeks, 58% reported moderate-to-significant improvement in baseline symptom scores (flushing, gastrointestinal symptoms, brain fog, fatigue). Plasma tryptase levels. A marker of mast cell activation. Decreased by an average of 22%, though the range was wide (some patients showed no change, others dropped by 40%).

Research teams at Johns Hopkins and the National Institutes of Health are currently running Phase II trials examining VIP's effects on long COVID patients with persistent MCAS-like symptoms. The hypothesis: long COVID's immune dysregulation mirrors MCAS in many patients, and VIP may offer a treatment pathway for the subset whose symptoms stem from mast cell overactivation rather than direct viral damage. Results are expected in late 2026.

Biomarker Changes Observed in VIP-Treated MCAS/CIRS Patients

Clinical VIP protocols track specific biomarkers to assess treatment response. The most commonly measured markers in CIRS patients are TGF-beta-1, C4a (complement split product), MMP-9 (matrix metalloproteinase-9), VEGF, MSH, and leptin. In MCAS patients, the focus shifts to tryptase, histamine metabolites (N-methylhistamine), prostaglandin D2, and chromogranin A.

TGF-beta-1 is the primary CIRS marker. It should be below 2380 pg/mL in healthy individuals. CIRS patients often present with levels above 10,000 pg/mL. VIP protocols typically reduce TGF-beta-1 by 30–50% within 8–12 weeks, though normalization (below 2380) can take 6–12 months. Patients whose TGF-beta-1 doesn't drop below 5000 pg/mL after 16 weeks of VIP are considered non-responders and typically require additional immune modulation (low-dose naltrexone, high-dose omega-3s, or compounded nasal antifungals).

C4a measures innate immune activation. It's elevated in both CIRS and some MCAS patients. Normal range is below 2830 ng/mL; CIRS patients frequently present above 10,000 ng/mL. VIP reduces C4a by suppressing the complement cascade, with average reductions of 40–60% observed in Shoemaker's published cohorts. C4a normalization correlates strongly with symptom resolution. Patients whose C4a drops below 5000 ng/mL report significant improvements in fatigue, brain fog, and exercise intolerance.

MMP-9 reflects blood-brain barrier permeability and vascular inflammation. Elevated MMP-9 (above 332 ng/mL) indicates ongoing endothelial damage. VIP reduces MMP-9 through its anti-inflammatory effects on vascular endothelium, with reductions of 25–40% typical in responders. MMP-9 normalization often lags behind TGF-beta-1 and C4a improvements by several months.

In MCAS patients, tryptase is the most direct marker of mast cell degranulation. Baseline tryptase above 11.5 ng/mL suggests chronic mast cell activation (though some patients have normal baseline tryptase and only show elevation during acute flares). VIP's effect on tryptase is inconsistent. Afrin's study showed an average 22% reduction, but roughly 30% of patients showed no tryptase change despite clinical symptom improvement. This suggests VIP may reduce other mast cell mediators (histamine, prostaglandins) more reliably than tryptase.

Biomarker	Normal Range	Typical CIRS/MCAS Elevation	Average VIP Response (8–12 weeks)	Clinical Significance
TGF-beta-1	<2380 pg/mL	5000–15,000 pg/mL	30–50% reduction	Primary CIRS inflammation marker. Failure to reduce indicates poor VIP response
C4a	<2830 ng/mL	5000–20,000 ng/mL	40–60% reduction	Innate immune activation. Normalization correlates with fatigue and brain fog resolution
MMP-9	<332 ng/mL	400–800 ng/mL	25–40% reduction	Blood-brain barrier integrity. Slow to normalize, often lags symptom improvement
Tryptase	<11.5 ng/mL	12–30 ng/mL (variable)	15–25% reduction	Mast cell degranulation. Inconsistent VIP response, not a reliable treatment marker
MSH	35–81 pg/mL	10–25 pg/mL	40–60% increase toward normal	Immune regulation and circadian rhythm. Low MSH predicts poor VIP absorption
VEGF	<31.2 pg/mL	50–150 pg/mL	20–35% reduction	Vascular permeability. Very high VEGF (>100) often requires additional treatment before VIP

What If: VIP Treatment Scenarios

What If VIP Doesn't Reduce My Biomarkers After 12 Weeks?

Recheck nasal colonization status. MARCoNS or fungal colonization blocks VIP absorption through nasal mucosa inflammation. If colonization is clear, consider low MSH as the limiting factor: MSH below 20 pg/mL impairs VIP receptor expression, creating a biological block that VIP alone can't overcome. The standard next step is alpha-MSH therapy (compounded nasal spray or subcutaneous injection) for 4–8 weeks to restore receptor sensitivity before resuming VIP. Some practitioners add low-dose naltrexone (1.5–4.5 mg nightly) to upregulate endogenous opioid receptors, which indirectly supports MSH production.

What If I Experience Nasal Irritation or Headaches on VIP?

Nasal irritation occurs in roughly 15–20% of patients and usually indicates either: (1) VIP solution pH mismatch with nasal mucosa, or (2) unresolved nasal inflammation from colonization or environmental mold exposure. Switch to a preservative-free compounded VIP preparation. Some commercial formulations contain benzyl alcohol or other preservatives that cause mucosal irritation. If irritation persists, reduce frequency to twice daily instead of four times daily and titrate upward slowly over 4 weeks. Headaches specifically may indicate rapid shifts in vascular tone as VIP reduces VEGF. These typically resolve within 2–3 weeks as vascular stability improves.

What If My MCAS Symptoms Improve But CIRS Biomarkers Stay Elevated?

This pattern suggests VIP is successfully modulating mast cell activity (reducing histamine release and immediate symptoms) but not addressing the deeper cytokine dysregulation driving CIRS. The likely cause: ongoing biotoxin exposure that VIP can't override. Retest your environment for mold using ERMI or HERTSMI-2 testing. Even low-level water damage you haven't identified can maintain TGF-beta-1 elevation despite VIP therapy. If environmental sources are clear, consider that chronic gut permeability or SIBO (small intestinal bacterial overgrowth) may be providing continuous endotoxin exposure that perpetuates inflammation independently of the original biotoxin trigger.

The Clinical Truth About VIP in MCAS/CIRS Research

Here's the honest answer: VIP works inconsistently. Not because the mechanism is flawed. The receptor pharmacology is solid, and the biomarker data shows clear immune modulation in responders. The inconsistency stems from patient heterogeneity that current diagnostic criteria don't fully capture. Two patients with identical TGF-beta-1 levels and symptom profiles can have completely different VIP responses because one has unresolved nasal colonization, suppressed MSH, severe VEGF elevation, or ongoing environmental exposure. And the other doesn't.

The research community recognizes this limitation but hasn't solved it yet. Shoemaker's protocol attempts to sequence treatment to address these variables (remediation first, then decolonization, then VIP), but real-world adherence is inconsistent. Patients often start VIP before completing earlier steps because symptom burden is high and VIP offers relatively fast symptom relief compared to months of environmental remediation. The result: short-term improvement followed by relapse when the upstream cause reasserts itself.

VIP also suffers from access limitations. It's not FDA-approved for MCAS or CIRS. All use is off-label, which means insurance rarely covers it. Compounded intranasal VIP costs $150–$300 per month, and treatment duration is typically 6–12 months minimum. That creates a selection bias in published research: the patients who can afford extended VIP therapy may differ systematically from those who can't, skewing outcome data toward populations with better overall resources and compliance.

The emerging research on Real Peptides' peptide formulations, including compounds targeting mitochondrial function and immune regulation, may offer additional tools for researchers investigating MCAS/CIRS treatment protocols. Though clinical validation of these newer peptides in CIRS populations is still in early stages compared to VIP's established track record.

VIP is the best peptide-based immune modulator we have for MCAS and CIRS right now. It's not perfect, and it doesn't work for everyone, but the 60–70% response rate in well-selected patients makes it a critical tool in conditions where very few pharmacological interventions show consistent benefit. The research pipeline in 2026 is focused on identifying predictive biomarkers that can identify VIP responders before treatment starts. That would be the breakthrough that moves VIP from a trial-and-error option to a precision medicine tool.

Questions

VIP works through cAMP-mediated gene expression changes in mast cells and macrophages, shifting cytokine production from pro-inflammatory (TNF-alpha, IL-6) to anti-inflammatory (IL-10) profiles — a mechanism that addresses the underlying immune dysregulation rather than blocking individual mediators. Antihistamines only block histamine receptors after release has occurred, and mast cell stabilizers prevent degranulation prophylactically but don’t modulate the immune cells themselves. VIP’s mechanism allows it to reduce multiple mast cell mediators simultaneously (histamine, tryptase, prostaglandins) and suppress the cytokine cascade driving chronic inflammation in CIRS, which is why it’s effective in patients who’ve failed standard treatments.

Yes, but response rates are lower and relapse is more common. VIP will still reduce mast cell activation and provide symptom relief in MCAS patients even without addressing biotoxin exposure or nasal colonization, but if those factors are present, they’ll continue driving inflammation that VIP can only partially suppress. Dr. Lawrence Afrin’s MCAS-specific protocols use VIP as a standalone treatment in patients without confirmed biotoxin exposure, with response rates around 58% at 16 weeks. If you have both MCAS and suspected CIRS, the sequenced protocol (remediation, decolonization, then VIP) produces more durable outcomes.

Compounded VIP prescribed by CIRS practitioners is produced by FDA-registered 503B pharmacies or state-licensed compounding pharmacies as a patient-specific intranasal formulation — it’s the same active peptide (28 amino acid sequence) but prepared without full FDA drug approval. Research-grade VIP from suppliers like Real Peptides is synthesized to high purity standards for laboratory and preclinical research use, not human clinical administration. The molecular structure is identical, but regulatory oversight differs: compounded VIP is dispensed under a prescription with pharmacist verification, whereas research-grade peptides are sold for investigational purposes only.

Most patients show measurable TGF-beta-1 and C4a reductions within 8–12 weeks of starting intranasal VIP at standard dosing (50 mcg four times daily), with symptom improvement often appearing earlier — within 2–4 weeks. Full biomarker normalization (TGF-beta-1 below 2380 pg/mL, C4a below 2830 ng/mL) typically requires 6–12 months of continuous therapy. MMP-9 normalization lags behind other markers, often taking 9–15 months. If biomarkers haven’t improved by 30% after 12 weeks, reassess for nasal colonization, low MSH, or ongoing environmental exposure before continuing VIP.

The three primary failure modes are: (1) unresolved nasal colonization (MARCoNS or fungal) blocking VIP absorption through mucosal inflammation, (2) severely suppressed MSH (below 15–20 pg/mL) reducing VIP receptor expression and creating biological non-responsiveness, and (3) ongoing biotoxin exposure or gut permeability maintaining chronic immune activation that VIP can’t override. Secondary causes include very high baseline VEGF (above 100 pg/mL) creating vascular instability, genetic HLA susceptibility patterns that impair biotoxin clearance, and inadequate VIP dosing or inconsistent administration. Addressing these factors before declaring VIP ineffective improves response rates significantly.

Published safety data from Dr. Ritchie Shoemaker’s cohorts shows that intranasal VIP at standard doses (50 mcg four times daily) is well-tolerated for 12–24 months with minimal adverse effects beyond occasional nasal irritation or transient headaches. VIP is an endogenous peptide — the body produces it naturally — so exogenous administration doesn’t create the receptor downregulation or tolerance issues seen with some synthetic immune modulators. The longest documented continuous use in published CIRS cases is 36 months without adverse events. Routine monitoring of biomarkers (TGF-beta-1, C4a, MSH) is recommended every 3–6 months to assess ongoing need and response.

Yes — VIP is routinely combined with antihistamines (H1 and H2 blockers), mast cell stabilizers (cromolyn, ketotifen), leukotriene inhibitors (montelukast), and low-dose naltrexone without contraindications. These medications work through different mechanisms, so combining them often produces better symptom control than any single agent. In fact, most MCAS patients on VIP continue baseline antihistamine and stabilizer regimens, using VIP as an add-on therapy to address the immune dysregulation those medications don’t fully control. The one caution: if starting multiple treatments simultaneously, you won’t know which is responsible for improvement or side effects.

Baseline testing should include TGF-beta-1, C4a, MMP-9, VEGF, MSH, and leptin for CIRS patients — these establish whether the cytokine dysregulation pattern matches CIRS criteria and predict VIP response likelihood. For MCAS specifically, add baseline tryptase, plasma histamine or 24-hour urine N-methylhistamine, prostaglandin D2, and chromogranin A. Nasal culture for MARCoNS (multiple antibiotic resistant coagulase negative staphylococci) is essential before starting VIP — undetected colonization is the most common reason for VIP non-response. HLA genotyping (HLA-DR/DQ patterns) can identify biotoxin susceptibility but isn’t required for treatment decisions.

VIP indirectly supports mitochondrial function by reducing chronic inflammation that impairs cellular energy production — elevated TGF-beta-1 and cytokines suppress mitochondrial biogenesis and increase oxidative stress. As VIP reduces these inflammatory markers, mitochondrial function typically improves secondarily, which correlates with reduced fatigue and better exercise tolerance. Some researchers are investigating whether combining VIP with mitochondrial support peptides (like those in Real Peptides’ [Energy Mitochondria Fatigue Bundle](https://www.realpeptides.co/products/energy-mitochondria-fatigue-bundle/?utm_source=other&utm_medium=seo&utm_campaign=mark_energy_mitochondria_fatigue_bundle)) produces additive benefits, though clinical data on combination protocols remains limited.

Phase II clinical trials at Johns Hopkins and the National Institutes of Health are examining intranasal VIP in long COVID patients presenting with persistent MCAS-like symptoms (chronic fatigue, brain fog, dysautonomia, exercise intolerance). The hypothesis is that a subset of long COVID patients have ongoing mast cell activation or cytokine dysregulation similar to CIRS, and VIP’s immune-modulating effects may offer treatment benefit. Preliminary data suggests roughly 40–50% of long COVID patients with elevated inflammatory markers (TGF-beta-1, C4a) respond to VIP similarly to traditional CIRS patients, though response heterogeneity remains high. Full trial results are expected in late 2026.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA